Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998
H. Weinstock et al., Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998, J INFEC DIS, 182(1), 2000, pp. 330-333
To assess the prevalence of mutations associated with decreased antiretrovi
ral drug susceptibility, specimens were tested from persons infected with h
uman immunodeficiency virus (HIV) during 1993-1998, Subjects were drug naiv
e and were attending sexually transmitted disease clinics in 6 US cities. A
ll were enrolled consecutively and had tested negative for HIV during the 2
years before enrollment. Plasma specimens from patients having greater tha
n or equal to 1 reverse transcriptase (RT) or primary protease mutation wer
e tested phenotypically with a recombinant virus assay. Of 99 patients, 6 (
6%) had mutations associated with zidovudine resistance, 2 (2%) had mutatio
ns associated with nonnucleoside RT inhibitor resistance, and 1 (1%) had a
primary protease mutation. Overall, the prevalence of resistance-associated
primary mutations was 5%, although high levels of decreased drug susceptib
ility (IC(50)s greater than or equal to 10 times that of a reference virus)
were observed in just 1%. These findings confirm the transmission of these
mutations to drug-naive persons.